Alnylam Pharmaceuticals (ALNY) is a publicly traded Healthcare sector company. As of November 18, 2026, ALNY trades at $156.63 with a market cap of $21.39B and a P/E ratio of 39.87. ALNY moved +0.08% today. Year to date, ALNY is -60.66%; over the trailing twelve months it is -66.01%. Its 52-week range spans $149.18 to $495.55. Analyst consensus is buy with an average price target of $310.55. Rallies surfaces ALNY's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Rallies tracks politician and congressional stock disclosures for ALNY, including purchases, sales, transaction dates, owners, and reported trade amounts when available.
| Metric | Value |
|---|---|
| Price | $156.63 |
| Market Cap | $21.39B |
| P/E Ratio | 39.87 |
| EPS | $5.53 |
| Dividend Yield | 0.00% |
| 52-Week High | $495.55 |
| 52-Week Low | $149.18 |
| Volume | 2 |
| Avg Volume | 0 |
| Revenue (TTM) | $4.80B |
| Net Income | $733.11M |
| Gross Margin | 79.79% |
26 analysts cover ALNY: 0 strong buy, 18 buy, 8 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $310.55.